| Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? A Lonardo, F Nascimbeni, A Mantovani, G Targher Journal of hepatology 68 (2), 335-352, 2018 | 638 | 2018 |
| Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis A Mantovani, CD Byrne, E Bonora, G Targher Diabetes care 41 (2), 372-382, 2018 | 536 | 2018 |
| Complications, morbidity and mortality of nonalcoholic fatty liver disease A Mantovani, E Scorletti, A Mosca, A Alisi, CD Byrne, G Targher Metabolism 111, 154170, 2020 | 388 | 2020 |
| Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis A Mantovani, G Zaza, CD Byrne, A Lonardo, G Zoppini, E Bonora, ... Metabolism 79, 64-76, 2018 | 316 | 2018 |
| Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies A Mantovani, CD Byrne, MH Zheng, G Targher Nutrition, Metabolism and Cardiovascular Diseases 30 (8), 1236-1248, 2020 | 305 | 2020 |
| Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals A Mantovani, G Petracca, G Beatrice, H Tilg, CD Byrne, G Targher Gut 70 (5), 962-969, 2021 | 285 | 2021 |
| Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis A Mantovani, E Rinaldi, C Zusi, G Beatrice, MD Saccomani, A Dalbeni Pediatric research 89 (4), 733-737, 2021 | 277 | 2021 |
| Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis A Mantovani, A Csermely, G Petracca, G Beatrice, KE Corey, TG Simon, ... The lancet Gastroenterology & hepatology 6 (11), 903-913, 2021 | 261 | 2021 |
| Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease QM Anstee, A Mantovani, H Tilg, G Targher Nature reviews Gastroenterology & hepatology 15 (7), 425-439, 2018 | 247 | 2018 |
| Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores G Targher, A Mantovani, CD Byrne, XB Wang, HD Yan, QF Sun, KH Pan, ... Gut 69 (8), 1545-1547, 2020 | 213 | 2020 |
| Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis A Mantovani, G Beatrice, A Dalbeni Liver international 40 (6), 1316-1320, 2020 | 189 | 2020 |
| Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled … A Mantovani, G Petracca, G Beatrice, A Csermely, A Lonardo, G Targher Metabolites 11 (2), 73, 2021 | 178 | 2021 |
| Patients with diabetes are at higher risk for severe illness from COVID-19 G Targher, A Mantovani, XB Wang, HD Yan, QF Sun, KH Pan, CD Byrne, ... Diabetes & metabolism 46 (4), 335, 2020 | 176 | 2020 |
| Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies A Mantovani, G Petracca, G Beatrice, A Csermely, H Tilg, CD Byrne, ... Gut 71 (4), 778-788, 2022 | 172 | 2022 |
| Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis A Mantovani, G Petracca, G Beatrice, A Csermely, A Lonardo, ... Gut 71 (1), 156-162, 2022 | 171 | 2022 |
| Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease A Mantovani, G Targher Annals of translational medicine 5 (13), 2017 | 170 | 2017 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 160 | 2022 |
| Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes G Targher, A Mantovani, I Pichiri, L Mingolla, V Cavalieri, W Mantovani, ... Diabetes care 37 (6), 1729-1736, 2014 | 159 | 2014 |
| Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes G Targher, A Mantovani, I Pichiri, R Rigolon, M Dauriz, G Zoppini, ... Clinical Science 125 (6), 301-310, 2013 | 154 | 2013 |
| Treatments for NAFLD: state of art A Mantovani, A Dalbeni International journal of molecular sciences 22 (5), 2350, 2021 | 135 | 2021 |
